All In Biotech

Drug Trial Radar · NCT06898047

Consistency of Response With Rimegepant in Acute Treatment of Migraine

CORRELATE-UK: COnsistency of Response With RimegEpant Oral Lyophilisate in Acute Treatment of migrainE in the United Kingdom

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

250

Actual

Start

Nov 15, 2025

Primary completion

Oct 24, 2026

Study completion Oct 24, 2026

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Mar 27, 2025

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a non-interventional, prospective study that will enroll participants with migraine in the United Kingdom currently in use of rimegepant to acutely treat migraine attacks. Participants will be followed up for up to 12 weeks and will complete a daily questionnaire to self-report the consistency of response to rimegepant in acute treatment of migraine.

Conditions

  • Migraine

Interventions

  • Rimegepant for acute migraine treatmentDrug

    Rimegepant for acute migraine treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Meaninful Pain Relief (MPR) post-dosingTime frame: Daily (within 24hs post dose)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Pfizer

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.